Liver TransplantNCT07101718
Outcomes and Risk Factors for Liver Transplantation Using Significant Fibrotic Grafts
An observational study of Liver Transplant, run by Zhejiang University at 1 site in China.
Trial summary
This is a multi-center study to investigate the impact of fibrotic liver greafts in liver transplant recipient. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Liver Transplant
- How many people
- 25,419 participants
- Where
- 1 siteChina
- Study dates
- 1 Jul 2024to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: A total of 25419 patients underwent liver transplant were studied.
Who may be able to join
- patients receiving liver transplantation during the period from March 2015 to March 2024
Who cannot join
- recipients under 18 years old
- re-transplantation cases
- multiorgan transplant cases, reduced-size or split LT cases
- lacking follow-up records or graft biopsy records
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Outcomes and Risk Factors for Liver Transplantation Using Significant Fibrotic Grafts: a Retrospective Cohort Analysis of the US National Database
This is a multi-center study to investigate the impact of fibrotic liver greafts in liver transplant recipient.
- Conditions
- Liver Transplant
- Being tested
- No intervention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
No intervention
| Study group | Role | What they receive |
|---|---|---|
| No fibrotic | Liver transplant recipient receiving no fibrotic liver grafts. Receives: Other: No intervention | |
| Mild fibrotic | Liver transplant recipient receiving mild fibrotic liver grafts. Receives: Other: No intervention | |
| Significant | Liver transplant recipient receiving significant fibrotic liver grafts. Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival rates
The overall survival of liver transplant recipients.
Measured: January 2015 to December 2024
Secondary outcomes (1)
Graft survival rates
The graft survival of liver transplant recipients.
Measured: January 2015 to December 2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2025
- Study start1 Jul 2024
- Primary completion10 Jul 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver TransplantStudies of the same condition, open and under way.
- More trials run by Zhejiang UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 25,419 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zhejiang University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiao Xu, Zhejiang University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07101718
- Sponsor's protocol ID
- CT-2025-ZJU-OBS07
- Status last verified
- Jul 2025
- First submitted
- 28 Jul 2025
- Last updated
- 3 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes and Risk Factors for Liver Transplantation Using Significant Fibrotic Grafts: a Retrospective Cohort Analysis of the US National Database
- ClinicalTrials.gov ID
- NCT07101718
- Acronym / sponsor ID
- CT-2025-ZJU-OBS07
- Conditions
- Liver Transplant
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 25,419 participants (actual)
- Lead sponsor
- Zhejiang UniversityUniversity, hospital or other
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 10 Jul 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 3 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-center study to investigate the impact of fibrotic liver greafts in liver transplant recipient.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| No fibrotic | – | Other: No interventionLiver transplant recipient receiving no fibrotic liver grafts. |
| Mild fibrotic | – | Other: No interventionLiver transplant recipient receiving mild fibrotic liver grafts. |
| Significant | – | Other: No interventionLiver transplant recipient receiving significant fibrotic liver grafts. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- A total of 25419 patients underwent liver transplant were studied.
Key inclusion criteria (1 listed)
- patients receiving liver transplantation during the period from March 2015 to March 2024
Key exclusion criteria (4 listed)
- recipients under 18 years old
- re-transplantation cases
- multiorgan transplant cases, reduced-size or split LT cases
- lacking follow-up records or graft biopsy records
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionNo intervention | Other | Mild fibrotic, No fibrotic, Significant |
Primary outcome
Overall survival rates
Time frame: January 2015 to December 2024
The overall survival of liver transplant recipients.
1 secondary outcome
Graft survival rates
Time frame: January 2015 to December 2024
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Liver Transplant
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
RecruitingPhase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Liver Transplant
RecruitingObservational study
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Transplant, run by Zhejiang University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival rates (time frame: January 2015 to December 2024). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2025.